Aurobindo Pharma Ltd. received a communication from the U.S. FDA classifying the inspection conducted at the API manufacturing facility of its Hyderabad plant as “Official Action Indicated”, according to a stock exchange filing.
- Co. says it believes that the inspection classification will not impact the continuing commercial supplies to the U.S. market from the facility
- The inspection was conducted between Aug. 2 and Aug. 12
- “The company will be engaging with the regulator and is fully committed in resolving the status of this facility at the earliest,” it said in the filing
- Aurobindo Pharma Ltd. rose 0.74% to 677 ...